Navigation Links
Worm 'cell death' discovery could lead to new drugs for deadly parasite
Date:9/28/2011

Researchers from the Walter and Eliza Hall Institute have for the first time identified a 'programmed cell death' pathway in parasitic worms that could one day lead to new treatments for one of the world's most serious and prevalent diseases.

Dr Erinna Lee and Dr Doug Fairlie from the institute's Structural Biology division study programmed cell death (also called apoptosis) in human cells. They have recently started studying the process in schistosomes, parasitic fluke worms responsible for the deadly disease schistosomiasis.

Dr Lee said that the group has shown that, unexpectedly, the cell death machinery that exists in fluke worms is remarkably similar to the cell death pathway in human cells. The finding was recently published in the journal Proceedings of the National Academy of Sciences USA.

"We found that schistosomes have a complex cell death mechanism that relied on a delicate balancing act of pro-survival and pro-death molecules, just like in humans," Dr Lee said. "Using the Australian Synchrotron, we also determined that the three-dimensional structure of a key schistosome cell death molecule was very similar to the protein which controls the process in humans. This structure is important because it will potentially guide future efforts to design drugs that target the schistosome cell death pathway."

More than 700 million people worldwide are at risk of schistosomiasis and 200 million people are currently infected, 85 per cent of whom live in Africa. Each year, an estimated 200,000 people die from the disease. The parasitic worm is carried by freshwater snails in contaminated water systems, and causes damage to the spleen, liver and other organs that can be fatal.

Dr Fairlie said that there is only one drug widely used for treating schistosomiasis, and concerns about the potential for drug resistance have increased the urgency for new drug targets and treatments. "Schistosomiasis ranks with malaria as a major source of human disease," Dr Fairlie said. "More than 2 billion people globally are at risk of parasitic worm infection, and we need to invest in the development of new drugs and vaccines, particularly as there are very few options currently available."

In the 1980s, scientists from the Institute and elsewhere discovered that defects in the cell death pathway were associated with cancer development. Dr Lee said the team are currently exploring the possibility that so-called 'BH3 mimetic' compounds such as ABT-737, discovered by biotechnology company Abbott, could also have a niche application for the treatment of parasitic worm diseases such as schistosomiasis. BH3 mimetics target the cell death pathway in humans and are currently being trialled as anti-cancer agents.

"The Bcl-2-regulated cell death pathway is currently being investigated as a therapeutic target for the treatment of some cancers," Dr Lee said. "We have found that a BH3-mimetic compound called ABT-737 binds to at least one schistosome pro-survival protein, suggesting it is feasible that BH3-like molecules could also be developed for treating schistosomiasis, and potentially other parasitic worm infections."

While the discovery leads to exciting new possibilities for the treatment of parasitic worm diseases, Dr Fairlie said there is still a lot to be understood about the cell death process in fluke worms before this becomes a reality. "Though we have found that this cell death pathway exists in the parasite, we don't yet know how important it is for the survival of the worm, or what the effect of drugs targeting the pathway will be. But we are excited about the possibility of developing an entirely new treatment strategy for schistosomiasis, which is a significant disease burden in developing countries," he said.


'/>"/>

Contact: Liz Williams
williams@wehi.edu.au
61-405-279-095
Walter and Eliza Hall Institute
Source:Eurekalert  

Related biology news :

1. Research reveals how dynamic changes in methylation can determine cell fate
2. Elsevier congratulates editors of Stem Cells: Scientific Facts and Fiction upon receipt of awards
3. Cell dysfunction linked to obesity and metabolic disorders
4. Mice stem cells guided into myelinating cells by the trillions
5. Protein switches could turn cancer cells into tiny chemotherapy factories
6. Cellular origin of a rare form of breast cancer identified
7. Team creates genetic GPS system to comprehensively locate and track inhibitory nerve cells
8. Scientists turn back the clock on adult stem cells aging
9. Spiral constriction -- how dynamin mediates cellular nutrient uptake
10. The cellular intricacies of cystic fibrosis
11. Why carbon nanotubes spell trouble for cells
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Worm 'cell death' discovery could lead to new drugs for deadly parasite
(Date:5/16/2016)... , May 16, 2016   EyeLock LLC , ... announced the opening of an IoT Center of Excellence ... and expand the development of embedded iris biometric applications. ... level of convenience and security with unmatched biometric accuracy, ... identity aside from DNA. EyeLock,s platform uses video technology ...
(Date:5/9/2016)... -- Elevay is currently known as the ... high net worth professionals seeking travel for work   ... there is still no substitute for a face-to-face meeting. ... deal with a firm handshake. This is why wealthy ... citizenship via investment programs like those offered by the ...
(Date:4/28/2016)... , April 28, 2016 Infosys ... (NYSE: INFY ), and Samsung SDS, a global ... that will provide end customers with a more secure, fast ...      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) , ... but it also plays a fundamental part in enabling and ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering ... retention in this eBook by providing practical tips, tools, and strategies for clinical ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. ... test has received AOAC Research Institute approval 061601. , “This is another AOAC-RI ... stated Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate ...
Breaking Biology Technology: